Skip to main content
logo
ADARx Pharmaceuticals, Inc. (ADRX)
NASDAQ: ADRX · Real-Time Price · USD
17.95
-0.18 (-0.99%)
At close: Oct 28, 2026, 4:00 PM EDT
18.43
+0.48 (2.67%)
Pre-market: Oct 29, 2026, 4:00 AM EDT

ADARx Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-87.87-73.09-46.36
Depreciation & Amortization
2.642.331.5
Loss (Gain) From Sale of Investments
-1.38-2.89-7.09
Stock-Based Compensation
5.596.133.95
Change in Accounts Payable
-0.814.47-0.22
Change in Unearned Revenue
-6.13331.55-
Change in Other Net Operating Assets
-0.37-6.21-0.34
Operating Cash Flow
-88.32262.29-48.56
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-1.89-2.94-0.46
Investment in Securities
82.91-206.9939.97
Investing Cash Flow
81.02-209.9339.51

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
0.020.10.23
Financing Cash Flow
0.020.10.23

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Foreign Exchange Rate Adjustments
0.120.020.01
Net Cash Flow
-7.1652.48-8.82

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-90.21259.35-49.02
Free Cash Flow Growth
---
Free Cash Flow Margin
-1472.37%7519.66%-
Free Cash Flow Per Share
-7.9522.82-4.46
Levered Free Cash Flow
--36.27-
Unlevered Free Cash Flow
--36.27-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-7.31329.81-0.56
SEC Filings: 10-K · 10-Q